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Objectives: Early allograft dysfunction after lung transplantation ranges
from subclinical x-ray abnormalities to pulmonary edema, hypoxemia,
hypercarbia, and pulmonary hypertension. Management may include extra-
corporeal circulation to allow recovery of the acute lung injury. We reviewed
our experience with extracorporeal membrane oxygenation after lung trans-
plantation to assess the utility of this therapy.
Methods: A retrospective chart review was performed. Single or bilateral
lung transplantation was performed in 444 adults from July 1988 to July
1998. Twelve (2.7%) patients experienced allograft dysfunction severe
enough to require extracorporeal membrane oxygenation after failure of con-
ventional therapy, including sedation, paralysis, and inhaled nitric oxide.
Results: Seven of 12 patients requiring extracorporeal membrane oxygena-
tion were discharged from the hospital. Mean and median times to extracor-
poreal membrane oxygenation support were 1.2 days and 0 days, respective-
ly. Mean length of support was 4.2 days. Four patients died while receiving
extracorporeal membrane oxygenation support. One patient was weaned
from extracorporeal membrane oxygenation but died during the hospitaliza-
tion. Two patients required acute retransplantation while receiving extracor-
poreal membrane oxygenation, and one survived to discharge. Three patients
continued to receive extracorporeal membrane oxygenation support for more
than 4 days, and all 3 died. All survivors had begun receiving extracorpore-
al membrane oxygenation support by post-transplantation day 1. Three of 7
patients discharged from the hospital died 12 months, 13 months, and 72
months after transplantation because of bronchiolitis obliterans syndrome (n
= 2) or lymphoma (n = 1). Four patients are alive 2, 12, 25, and 54 months
after transplantation.
Conclusions: Extracorporeal membrane oxygenation provides effective ther-
apy for acute post-transplantation lung dysfunction. The frequency and pat-
tern of our extracorporeal membrane oxygenation use reflects bias toward
early extracorporeal membrane oxygenation support for isolated graft failure
in otherwise intact and uninfected recipients. (J Thorac Cardiovasc Surg
2000;120:20-8)
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D espite progress in donor lung preservation and sur-gical technique of lung transplantation, early graft
dysfunction remains a major postoperative problem.
Estimates of the frequency of this problem range from
15% to 30% of transplant operations. The actual preva-
lence is difficult to ascertain because the syndrome has
been described as multiple entities: reperfusion edema,
reimplantation response, primary graft failure, and pro-
longed postoperative ventilator dependence. The syn-
drome includes infiltrates on chest radiograph, impair-
ment in oxygenation, and graft biopsy histology of
diffuse alveolar damage. The severity ranges from a
trivial subclinical radiographic finding to full-blown
adult respiratory distress syndrome. The pathophysiol-
ogy involves a combination of increased permeability
of the pulmonary capillary bed and increased pul-
monary vascular resistance leading to transient pul-
monary hypertension. Rejection, bacterial pneumonia,
cytomegalovirus pneumonitis, and pulmonary venous
obstruction can mimic the syndrome.
Standard treatment in moderate and severe cases
includes vigorous diuresis and extended support with
positive-pressure ventilation. Sedation and paralysis
are typically used to improve the efficiency of the ven-
tilator and decrease oxygen consumption. We previous-
ly reported that inhaled nitric oxide improves gas
exchange in patients with severe early allograft dys-
function.1 In very severe cases extracorporeal mem-
brane oxygenation (ECMO) has been necessary to sup-
port gas exchange until the recovery of the lungs. We
retrospectively reviewed our use of ECMO in the set-
ting of postoperative lung dysfunction after lung trans-
plantation to assess the likelihood of success of this sal-
vage therapy as measured by weaning from ECMO,
discharge from the hospital, and eventual long-term
survival. We also sought to identify characteristics of
successful and unsuccessful uses of post-transplanta-
tion ECMO to guide future use of this therapy.
Patients and methods
A retrospective chart review was performed. Single or bilat-
eral lung transplantation was performed in 444 adults from
July 1988 to July 1998. Twelve (2.7%) patients experienced
allograft dysfunction severe enough to require ECMO after
failure of conventional therapy, including sedation, paralysis,
and inhaled nitric oxide. The decision to use ECMO was made
by the surgeon in the 6 patients requiring ECMO on the day of
surgery. In the remaining 6 patients ECMO was used after the
joint determination by the surgeon and the transplant pulmo-
nologist that conventional management was failing. Ten
patients had received bilateral transplants, and two had
received single lung transplants. Table I contains the graft
ischemic times and cardiopulmonary bypass (CPB) times for
these patients. Reperfusion injury is the most prevalent reason
for immediate and early lung dysfunction, but not all of the
patients in this report could be described as fitting that diag-
nosis. The first patient in this series began receiving ECMO
for hypotension and hemodynamic instability that was other-
wise unmanageable with pressors. The third patient in the
series underwent a cardiovascular collapse on weaning from
CPB. The failure to wean was eventually attributed to a tech-
nically unacceptable pulmonary venous anastomosis. All
other patients began receiving ECMO for the characteristic
picture of reperfusion injury and primary graft dysfunction:
hypoxemia, hypercarbia, acidosis, increased pulmonary arter-
ial pressures, and decreased ventilatory compliance of the
lungs. The most recently treated patient fit the profile for
reperfusion injury, but a diligent search for technical errors
identified a pressure gradient across a pulmonary artery anas-
tomosis that was subsequently revised on ECMO support.
Operative techniques. In all cases venoarterial ECMO
support was provided. In the first 3 patients treated in this
manner, we performed the ECMO cannulation by means of
femoral artery and femoral vein cannulations. In 8 of the sub-
sequent 9 patients, we avoided groin cannulation and chose to
cannulate the ascending aorta and the right atrium directly.
The oxygenator used for the ECMO circuit was a silicone
rubber membrane model #I 4500-2A from Avecor (Plymouth,
Minn), and the pump was a centrifugal blood pump from
Medtronic Inc (Eden Prairie, Minn).
Conduct of ECMO. Most patients were moderately or
severely coagulopathic at the time of cannulation. Heparin
was therefore typically withheld for 12 to 24 hours to allow
correction of the coagulopathy. Heparin infusion was then
titrated to maintain an activated clotting time of 180 to 250
seconds. Special care was given to ensure adequate
heparinization during the weaning from ECMO. ECMO
flows were typically 2.5 to 3.5 L/min. All patients had pul-
monary arterial catheters, and ECMO flows were titrated to
ensure evidence of right ventricle ejection as measured by
systolic peaks on the pulmonary artery catheter. Once ECMO
had been established, we decreased the rate and tidal volume
of the ventilator to minimize barotrauma but maintain mod-
erate levels (10-15 cm H2O) of end-expiratory pressure. The
decision to wean from ECMO was based on the appearance
of the lungs on chest x-ray film and the response of the
patient’s oxygenation, ventilation, airway pressures, and pul-
monary artery pressures to lower ECMO flow rates and
resumption of standard ventilator settings. 
Statistical methods. Continuous data are described by use
mean values ± 1 SD. A 2-sample t test with Bonferroni cor-
rection was used to compare ischemic times of ECMO and
non-ECMO transplant recipients. The Fisher exact test was
used to analyze the frequency of ECMO use in subgroups of
our entire transplant population sorted by sex, diagnosis, and
type of transplant (single vs bilateral). A paired t test was
used to compare blood gas results and pulmonary pressures
before and after the start of ECMO support. A logistic regres-
sion was used in an attempt to identify statistically significant
risk factors in the 12 patients receiving ECMO when com-
pared with the 432 patients undergoing transplantation with-
out subsequent need for postoperative ECMO.
Results
We have used ECMO in 12 lung recipients since the
inception of the lung transplant program at Washington
University. Clinical data recorded on these patients are
summarized in Table I. The patients requiring ECMO
included 11 women and 1 man out of an overall popu-
lation of transplant recipients including 225 women
and 219 men. The mean age was 38 ± 11 years. The
mean ischemic time to the first lung was 301 ± 67 min-
utes, and the mean ischemic time to the second lung (in
the 9 bilateral transplants) was 390 ± 92 minutes. These
times were not significantly different from ischemic
times for our transplant recipients as a whole: 283 ± 77
minutes for the first lung (P = .74) and 328 ± 98 min-
utes for the second lung (P = .13). Ten of the 12
patients underwent bilateral transplants. The underly-
ing diagnoses leading to transplantation included pul-
monary hypertension in 5 patients, cystic fibrosis in 3
patients, and emphysema, pulmonary fibrosis, sar-
coidosis, and bronchiectasis in 1 patient each. The
prevalence of ECMO use in patients with pulmonary
hypertension (5/51 [9.8%]) was higher than the preva-
lence in patients with other diagnoses (7/293 [1.8%]).
All patients had been stable outpatients until the day of
transplantation.
The initiation of ECMO support took place on the
day of surgery in 6 patients, on postoperative day 1 in
4 patients, and on postoperative days 2 and 8 in 1
patient each. The 6 patients receiving ECMO on the
day of surgery included 4 who began receiving
ECMO in the same operation as the transplant and 2
who had brief trials of conventional ventilator and
pharmacologic support in the intensive care unit
before returning to the operating room for cannula-
tion. ECMO support was continued for a time period
ranging from 1 to 10 days, with a mean of 3.6 ± 2.9
days.
The goal of ECMO in this situation is to maintain
adequate oxygenation and ventilation, decrease pul-
monary artery pressures to decrease the transcapillary
gradient in the pulmonary vasculature, and allow
reduction in the rate and tidal volume of mechanical
ventilation to limit secondary ventilator-induced baro-
trauma. Table II contains the blood gas results, airway
pressures, and mean pulmonary arterial pressures for
these patients at the time of ECMO cannulation and 4
hours after the initiation of ECMO support. The arte-
rial pH improved from 7.29 ± 0.11 to 7.39 ± 0.07 (P
= .005) in the first 4 hours of ECMO. Similarly, the
PO2 increased from 52.2 ± 8.4 to 231 ± 78.4 (P =
.001), and the PCO2 fell from 46.3 ± 11.8 to 33.9 ± 3.6
(P = .003). The peak inspiratory pressures fell from
63.3 ± 14.7 cm H2O to 37 ± 4.0 cm H2O (P = .001).
Mean pulmonary artery pressures fell from 39.2 ± 8.9
mm Hg to 18.5 ± 6.8 mm Hg (P = .001). The fraction
of inspired oxygen was reduced from a mean of 1.00
± 0.0 to 59.2 ± 21.9 in the 4 hours after ECMO can-
nulation (P = .001).
Complications experienced during or after ECMO
support are summarized in Table III. Ten patients had
notable postoperative bleeding with multiple transfu-
sions. Seven patients required re-exploration specifi-
cally for bleeding. Renal failure developed in 7 patients
to the extent that temporary dialysis or ultrafiltration
was required. Four patients were noted to have neuro-
logic injury of some kind, 2 who subsequently recov-
ered completely and 2 with massive strokes, which led
to decisions to terminate further support.
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Table I. General characteristics of patients treated with ECMO
Transplant Ischemic time, Ischemic time, CPB time
Patient Sex Diagnosis type first graft (min) second graft (min) (min)
1 F PH Single 480 NA 211
2 F CF Bilateral 300 523 315
3 F PH Single 275 NA 297
4 F CF Bilateral 330 480 104
5 F PH Bilateral 265 310 267
6 F PH Bilateral 270 300 280
7 F Sarcoidosis Bilateral 198 310 99
8 F PH Bilateral 290 315 269
9 F Bronchiectasis Bilateral 257 511 204
10 M IPF Bilateral 307 363 None
11 F CF Bilateral 330 330 197
12 F COPD Bilateral 314 464 None
PH, Pulmonary hypertension; NA, not applicable; CF, cystic fibrosis; IPF, idiopathic pulmonary fibrosis; COPD, chronic obstructive pulmonary disease.
The overall survival results of our experience with
ECMO support after lung transplantation is recorded in
Table IV and includes 7 patients who survived to be
discharged from the hospital and 5 patients who died
during the postoperative hospitalization. Of the 5
patients who died, 4 died when all support, including
ECMO, was withdrawn after a consensus was reached
by the team of physicians and each patient’s family that
irreversible multisystem organ failure had made the sit-
uation hopeless for recovery. One patient was success-
fully weaned from the ECMO circuit only to die sever-
al weeks later of anoxic encephalopathy, acute renal
failure, and Pseudomonas species sepsis.
A logistic regression was used to determine whether
patient characteristics could define a subgroup of
patients at statistically increased risk for graft failure
requiring ECMO. The ability to make these inferences
is limited by several factors: One was the small number
of patients receiving ECMO (n = 12) versus patients
not receiving ECMO (n = 432). Also, the coarse binary
nature of the response variable (ECMO vs non-ECMO)
further limits the leverage of statistical procedures in
these patients. The studied variables included ischemic
time, transplant type (single vs bilateral), recipient
diagnosis, donor quality (ideal or marginal), age, sex,
CPB time, and preoperative mechanical ventilation
(yes or no). When the variables are considered alone,
age, sex, recipient diagnosis, and CPB time were all
significant factors as recorded in Table V. Several mul-
tivariate models were then constructed in an attempt to
identify important variables that identify patients at
higher risk for requiring postoperative ECMO support.
None of these models had the sensitivity or specificity
to adequately discriminate between the patients receiv-
ing and not receiving ECMO, and as a result, the con-
clusion was made that the data do not offer adequate
information to assess ECMO risk factors.
One statistical model looked only at women who had
received bilateral transplants. This group included 9
patients receiving ECMO and 122 patients not receiv-
ing ECMO. When variables were evaluated separately,
the following factors were significant in identifying
patients receiving ECMO: ischemic time (P = .02),
diagnosis of pulmonary hypertension (P = .036), and
use of CPB (P = .005). Two joint models were evaluat-
ed, one using CPB and one omitting CPB on the
grounds that its use was influenced by lung failure
leading to ECMO, and it was thus artifactually linked
to ECMO. In the joint model without CPB considered,
ischemic time (P = .006) and diagnosis of pulmonary
hypertension (P = .014) were significant. In the model
using CPB as a variable, only ischemic time (P = .007)
and CPB use (P = .008) were significant.
Discussion
Our experience and that described by others suggest
that there is a definite role for ECMO in treating acute
donor lung dysfunction. In the most favorable scenario,
acute postoperative graft dysfunction begins almost
immediately and presents as pulmonary edema with
hypoxemia and noncompliant lungs. This immediate
dysfunction is almost always reversible, and ECMO
support is advisable when conventional ventilatory
strategies prove inadequate. Indeed, an argument can
be made for the use of ECMO early in the course of a
rapidly evolving reperfusion injury, rather than as a
last-ditch heroic maneuver to salvage what may, by that
time, be an irreversible lung injury. In most cases the
graft lung will heal and the pulmonary edema will
resolve, allowing for improved oxygenation and venti-
lation within 1 to 5 days. The use of ECMO is associ-
ated with substantial risk, and there is a high morbidity
and mortality in the patients treated in this manner.
The pattern of use of ECMO described in this report
is conservative compared with that seen in reports from
other centers. To better understand our own habits in
using ECMO, we reviewed the hospital charts of the 2
patients in our transplant database who died of primary
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Table III.  Complications of ECMO support
ECMO complications Patients, n (%)
Coagulopathy, multiple transfusions 10 (83)
Re-exploration for bleeding 7 (58)
Renal failure requiring support 7 (58)
Stroke 3 (25)
Arterial injury at cannulation site 1 (8)
Other 3 (25%)
Table II.  Response of physiologic profile to ECMO
support
Pre-ECMO 4 hours of ECMO P value
pH 7.29 ± 0.11 7.39 ± 0.07 .005
PO2 (mm Hg) 52.2 ± 8.4 230 ± 78 .001
PCO2 (mm Hg) 46.3 ± 11.8 33.9 ± 3.6 .001
FIO2 (%) 100 ± 0 59.2 ± 21.9 .001
PIP (cm H2O) 63.3 ± 14.7 37.4 ± 4.0 .001
PAP (mm Hg) 39.2 ± 8.9 18.5 ± 6.8 .001
FIO2, Fraction of inspired oxygen; PIP, peak inspiratory pressure; PAP, pul-
monary arterial pressure.
graft failure without the use of ECMO. These patients
are mentioned to emphasize our own selectivity of
ECMO use and not to suggest that their outcome might
have improved with the use of ECMO. One man had a
stormy postoperative course after a bilateral transplant
for idiopathic pulmonary fibrosis. He underwent an
episode of ischemic colitis leading to colectomy on
postoperative day 14 and had persistent pulmonary
dysfunction and pulmonary hypertension. He died of a
massive endobronchial hemorrhage on postoperative
day 38, and the cause of death was determined to be
diffuse alveolar damage with acute hemorrhage. The
other patient was a woman with primary pulmonary
hypertension who underwent single-lung transplanta-
tion and closure of a patent foramen ovale by means of
a median sternotomy. She did poorly from the start,
with severe pulmonary hypertension, right ventricular
dysfunction, poor gas exchange, and hypotension
necessitating high-dose pressors. She later had renal
and hepatic failure, as well as thrombocytopenia.
Because of her multiorgan dysfunction, we declared
that ECMO was not indicated, and she died on postop-
erative day 8.
The prevalence of women in this group of patients
requiring ECMO is difficult to explain. Eleven of the
12 patients described in this report are women, yet the
overall population of lung transplant recipients in our
institution is very evenly distributed according to sex:
219 men and 224 women at a recent count. It is quite
possible that either the smaller size of the female recip-
ient or the smaller size of the graft lung make preser-
vation of the lung more difficult. In particular, our habit
of using iced laparotomy sponges around the lung as it
is implanted is made more difficult when the pleural
space is small. This problem was specifically men-
tioned in at least one operative note of a patient who
eventually required ECMO. Also, the smaller size of
the pulmonary vessels being anastomosed decreases
the tolerance for technical error. Finally, patients with a
diagnosis of primary or secondary pulmonary hyper-
tension are represented out of proportion to their preva-
lence in our entire transplant experience, and the
majority of these patients are women.
For those patients receiving ECMO, the prevalence
of female sex is in part dependent on the recipient diag-
nosis of pulmonary hypertension. This problem is rep-
resentative of multiple codependencies seen in the data
collected on these patients. For instance, patients
undergoing transplantation with CPB who are in good
physiologic condition will be removed from the CPB
support very quickly after reperfusion of the graft lung
or lungs. If these patients are acutely unstable and
require ECMO, the CPB support will be extended until
an ECMO circuit is prepared and inserted into the per-
fusion system. Thus the patients receiving ECMO will
have longer bypass runs than patients not receiving
ECMO, but it is misleading to conclude that the longer
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Table IV.  Result of ECMO on lung recovery and patient survival
Patient ECMO start ECMO days Weaned Outcome Comment
1 0 3 Yes Lived
2 1 1 Yes Lived
3 0 4 Yes Died Weaned but died 4 weeks later; brain death
4 0 3 Yes Lived
5 0 4 Yes Lived
6 1 10 No Died Failure to improve; support withdrawn
7 2 10 No Died Massive hemorrhage
8 8 1 No Died Brain death
9 1 1 Yes Lived Successful retransplant
10 1 8 No Died Failed retransplant
11 0 4 Yes Lived
12 0 1 Yes Lived
ECMO start, Days elapsed between lung transplant and ECMO cannulation; ECMO days, length of ECMO support; weaned, removed from ECMO circuit before
death.
Table V.  Univariate analysis of risk factors for
ECMO use
Variable χ2 P > χ2
Ischemic time 2.77 .096
Recipient age 4.51 .034
Donor PO2 0.29 .6
Donor quality 0.07 .8
Vented 0.39 .54
Single versus bilateral 0.82 .37
CPB time 12.06 .0005
Sex 5.19 .023
Pulmonary hypertension 4.4 .036
Donor PO2, Partial pressure of oxygen in donor under standard conditions of
100% inspired oxygen and 5 cm H2O end-expiratory pressure.
bypass run caused the need for the ECMO support.
Similarly, in a bilateral transplant started without
bypass, immediate dysfunction of the first transplanted
lung will cause an interruption in the flow of the oper-
ation to cannulate for bypass. This will prolong the
ischemic time for the second lung. If this patient later
requires ECMO, the longer ischemic time may be
viewed as a partial cause of the need for ECMO, when
in fact the long ischemic time is a result of the imme-
diate dysfunction of the first lung. Finally, patients with
some diagnoses (cystic fibrosis and pulmonary hyper-
tension) tend to be much younger than patients with
other diagnoses (idiopathic pulmonary fibrosis and
chronic obstructive pulmonary disease), and this partial
dependency of age on diagnosis will cloud conclusions
about the role of recipient age on the subsequent risk
for ECMO support.
With regard to technical considerations, our preferred
ECMO cannulation sites are the ascending aorta and
right atrium, whereas others have advocated a femoral
arterial and venous cannulation. The main putative
benefit of femoral cannulation is avoidance of a thora-
cotomy for the insertion and subsequent removal of the
ECMO circuit. Because the majority of our patients
have required re-exploration of the chest to evacuate
blood and search for bleeding sites, this potential ben-
efit is minimized. Furthermore, the majority of our
patients (11/12) have been women, and the smaller size
of the femoral vessels increases the likelihood of com-
plications of a groin cannulation. We had one such
complication and have subsequently chosen to use tho-
racic cannulation whenever possible. A more unusual
complication of femoral ECMO has been reported by
others in which the lower half of the body receives the
well-oxygenated ECMO blood while the upper half of
the body receives the poorly oxygenated blood leaving
the lungs.2 A phenomenon such as this cannot occur
with thoracic cannulation.
Early lung dysfunction after transplantation remains
a problem despite continued progress in graft preserva-
tion. Standard therapy, consisting of mechanical venti-
latory support and pharmacologic reduction of pul-
monary arterial pressures, is based on the knowledge
that most cases of reperfusion injury are transient and
completely reversible. The drawback of standard thera-
py is that stiff edematous lungs require high drive pres-
sures for ventilation, and this inevitably leads to a sec-
ondary barotrauma superimposed on the primary graft
dysfunction. Additionally, the alprostadil (prosta-
glandin E1) used to decrease the pulmonary artery pres-
sures inevitably causes varying degrees of systemic
hypotension. The goal of ECMO is to assist with gas
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exchange and systemic perfusion while allowing the
lungs to heal without the additional injury caused by
the ventilator.
Since the first report of combined therapy with
ECMO support with lung transplantation in 1978, these
two therapies for lung failure have been combined in
every way imaginable. Several authors have reported
use of ECMO to support pretransplant patients until a
graft is available. In some cases ECMO provides a
direct bridge to transplantation, but in several patients
the ECMO was used for a brief period of acute exacer-
bation of the lung failure and was not needed right up
to the time of transplantation.3-9
The most common pairing of lung transplantation
and ECMO is the scenario described by our experience
in this article: the support of a post-transplant recipient
during an episode of reversible acute lung dysfunc-
tion.3,4,6,10-19 In some instances it becomes apparent
that the acute post-transplant lung dysfunction may not
be reversible. In these rare cases the goal of ECMO
changes and becomes support of post-transplant recip-
ient until retransplantation is performed. Another dis-
tinct pattern of ECMO use after transplantation is the
support of a post-transplant recipient during late lung
dysfunction. This category is subjective, and the transi-
tion from early to late lung dysfunction varies accord-
ing to authors’ whims. Some authors have considered
acute lung injury to include the need for ECMO within
48 hours of transplantation, with subacute and late fail-
ure being defined as 2 to 7 days and more than 7 days,
respectively.10 Others have declared early lung dys-
function to mean less than 7 days after transplantation
and late dysfunction to mean 7 days or more after
transplantation.11 The final and most unusual combina-
tion of ECMO and transplantation is the prophylactic
support of a transplant recipient to prevent acute lung
dysfunction.20 The single cited case report describes
the authors’ desire to minimize the likelihood of life-
threatening reperfusion injury by performing the trans-
plant on ECMO and keeping the patient supported with
ECMO for several days postoperatively until the early
risk of reperfusion edema has passed.
Eriksson and Steen21 have reported a novel therapeu-
tic approach to life-threatening dysfunction of the
newly transplanted lung. They reported 2 cases in
which primary graft failure, with a severity meeting
their criteria for institution of ECMO, was managed
with induced hypothermia, sedation, muscle relaxation,
steroids, and isotonic buffers to stabilize the patients
and reduce their metabolic activity. Both patients sur-
vived without ECMO or retransplantation. In the
absence of novel strategies such as this one, the only
alternatives for severe early lung dysfunction after
transplantation are conventional ventilation and phar-
macologic manipulation of pulmonary artery pressures
or ECMO.
Conclusions
We conclude that ECMO support in the setting of
acute post-transplantaation pulmonary failure is rea-
sonable therapy with an acceptable likelihood of suc-
cess. Extracorporeal support allows normal gas
exchange and an immediate reduction in peak airway
pressure and pulmonary artery pressure and thereby
minimizes additional reperfusion pulmonary edema
and secondary barotrauma. The highest likelihood of
success will be in patients with a technically sound
operation in whom reperfusion injury is identified
immediately and treated with ECMO without delay.
Extracorporeal support is associated with a high risk
of renal and neurologic impairment, which limits its
attractiveness as a therapy for less severe reperfusion
injury. Patients with delayed failure of the transplant-
ed lung have more complex disease and are less like-
ly to have the predictable favorable response to
ECMO.
We gratefully acknowledge the help of Richard B.
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Discussion
Dr Frederick Grover (Denver, Colo). This article reviews
the Washington University Barnes Hospital experience for
the use of ECMO for end-stage pulmonary graft failure after
lung transplantation. Of the 444 lung transplants performed
during the 10-year period, 2.7% or 12 patients required
ECMO for allograft dysfunction that defied conventional
therapy. Seven of these 12 patients survived. This is a very
good survival figure for this desperately ill group of patients
who otherwise very likely would not have survived without
the use of ECMO. Of particular interest is the fact that 10 of
12 had a bilateral sequential transplant, 11 of the 12 were
women, and 5 underwent transplantation because of pul-
monary hypertension. Very good results were seen in terms of
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the physiologic improvement of these patients. As you men-
tioned, this is a high-morbidity procedure with bleeding,
renal dysfunction, and a high incidence of stroke and irre-
versible brain damage.
Our experience at the University of Colorado is very simi-
lar. We are also conservative in the use of ECMO and use
many of your indications. Our use of this in 138 transplants
we performed over the last 8 years is 2.2% compared with
your 2.7%. Actually, of the 3 in which we used ECMO, 1
patient had an acute myocardial infarction; therefore, we had
2 with graft failure. One of our 2 patients is alive and well 6
years after the operation. Therefore, it is a useful procedure in
many of our hands.
I have several questions for Dr Meyers and his group. The
incidence of female sex and pulmonary hypertension in your
ECMO group was significantly greater than that found in
your transplant population as a whole, which you demon-
strated. Have you done a multivariate analysis to separate out
whether these are both independent risk factors because the 5
patients with persistent pulmonary hypertension were all
women?
Dr Meyers. No I have not, although I think we will have to
do that. It is worrisome that 11 of the 12 were women and that
all 5 pulmonary hypertensive patients were women; there-
fore, a multivariate analysis will be necessary to dissect out
which is the leading cause. The patients with pulmonary
hypertension and the women do share a characteristic that
might lead to inadequate preservation of the lung, even if the
ischemic times are not significantly longer. Our personal
technique of keeping the donor lung cool during implantation
depends on placement of iced lap pads around the graft lung
as it is being implanted. Patients with a large chest volume
relative to the volume of the implanted lung allow us a much
better ability to keep the graft cold while it is being implant-
ed. I think women and pulmonary hypertensive patients tend
to have small chest volumes in relation to the size of the lung
being implanted. They may share this characteristic, but it
will take multivariate analysis to distinguish the leading risk
factor.
Dr Grover. Although your analysis showed that the
ischemic times of your ECMO group were not statistically
significantly longer than those of your population as a whole,
they were longer nevertheless. I think the second lung in your
bilateral sequential group had an average ischemic time of 1
hour longer in your ECMO group compared with your group
as a whole, and there were 4 patients who had ischemic times
of greater than 8 hours. Therefore, because this is a relatively
rare event and your numbers are relatively small, do you think
that the trend is there, even though findings were statistically
insignificant in this area? Do you think that ischemic time
probably is indeed a predictor of this?
Dr Meyers. I would agree. I think that there is a trend, and
if more patients had required ECMO, it might have fallen out
as being significant. I also noticed that the difference in the
ischemic time for the first lung was much smaller than that
for the second lung, and many of these patients actually had
problems on implantation of the first lung. The delay in
implanting the second lung was often cannulation for bypass
and trying to correct that problem with the first one. The
longer ischemic time on the second lung is skewed a bit by
the fact that problems have already arisen, and much of that
time is cold ischemic time, which does not greatly affect
function. 
Dr Grover. That may lead into my final question, which
concerns the potential effect of CPB on lung dysfunction.
CPB was used in 10 of your 12 patients, and obviously 5 of
those had persistent pulmonary hypertesion. Therefore, I
think all of us would use bypass in those individuals, but in 4
it exceeded 8 hours. Maybe this is a question of what goes
first, the horse or the cart, but we have found an association
in our experience in Denver with the use of CPB and lung
dysfunction. Have you analyzed the data in this regard?
Dr Meyers. No, I have not. You mentioned the 8-hour
time frame. I think there were a couple of ischemic times
that ran 8 hours. The range of time for CPB went from 99
minutes for the shortest bypass run to 315 minutes. The lat-
ter is a pretty substantial bypass run. When I take the next
step with the multivariate analysis, the use of CPB will be
included in the analysis. Our overall rate of use of CPB is
about 25% for the entire cohort. Therefore, certainly 10 of 12
is an overrepresentation. Again, when the patients are having
difficulty with pulmonary edema and poor oxygenation imme-
diately after the first lung is unclamped, a response in many
cases is to begin CPB. In those cases the dysfunction leads to
CPB rather than the other way around, as you postulate.
Dr Richard Whyte (Stanford, Calif). A few years ago,
back in Michigan, we looked at a similar group of patients
who required ECMO support after heart and lung transplan-
tation. In those patients undergoing lung transplantation, we
did not have the benefit of nitric oxide. Do you think that
nitric oxide has decreased the need for ECMO, particularly in
your patients requiring single-lung transplantation?
Dr Meyers. We started using nitric oxide in 1994, and
therefore the last 6 of the 12 patients had the benefit of nitric
oxide. It is hard to know which component of the overall care
has led to a gradual decrease in the frequency. When I look
back, there has been approximately one patient per year over
the 10 years, with the exception of 1996, yet the volume of
transplants each year has increased. Therefore, the frequency
has decreased over time. Nitric oxide certainly has been one
component of that decrease. Other work by Drs Patterson and
Cooper and the rest of our group has shown that nitric oxide
can help either mitigate or eliminate early lung dysfunction.
Nitric oxide probably played a role, but it is difficult to know
what role it did play and what other improvements in the
process contributed to the falling incidence of ECMO use.
Dr Whyte. You have clearly shown that the outcome in
these patients who require ECMO is not very good overall.
These patients are critically ill, but you certainly showed that
some of these patients who otherwise would die can be sal-
vaged with this technique.
Dr Joseph Arcidi (Salt Lake City, Utah). Having partici-
pated in this experience, I know that the philosophy of trans-
plantation for pulmonary hypertension at Washington
early years of this experience, they made up probably 20% of
all patients on whom we performed transplantation. Now the
percentage is probably about 5%. As a result, 5 of the first 6
patients in this experience had pulmonary hypertension, and
only 1 of the last 6 had pulmonary hypertension. When they
do undergo transplantation, our tendency now is to opt for
bilateral transplantation.
Dr Arcidi. Is it possible to separate out the causes of stroke
and renal failure from ECMO or the insult before instituting
ECMO in these patients?
Dr Meyers. I do not know. Of the patients who eventually
were found to have strokes, none had a period of lucency dur-
ing which we could demonstrate that they made it through the
transplant neurologically intact and the injury was inflicted
by ECMO. They basically never regained consciousness to
any certain extent after the transplant. 
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University has sometimes favored single-lung transplantation
and sometimes favored bilateral transplantation. Has the fre-
quency with which you perform bilateral transplantation for
pulmonary hypertension affected the incidence of requiring
ECMO or nitric oxide for support of those patients with lung
dysfunction afterward?
Dr Meyers. With regard to the use of nitric oxide: we start
all patients on it after transplantation. We bring it into the
operating room, and if it is a bilateral transplant, we start it
running when we start perfusing the first graft. When we get
to the intensive care unit, if the pulmonary function is good
and the pulmonary artery pressures are low, we wean it off
fairly rapidly. The focus of questions today on the pulmonary
hypertensive patients is expected on the basis of their relative
frequency in this group. Unfortunately, or fortunately, they
are not being referred for transplantation anymore. In the
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